{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:24:02Z","timestamp":1791329042923,"version":"4.3.1"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bmc.2024.117874","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T23:27:42Z","timestamp":1723850862000},"page":"117874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Recent advances in the treatment of gout with NLRP3 inflammasome inhibitors"],"prefix":"10.1016","volume":"112","author":[{"given":"Ye","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusen","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117874_b0005","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.medcli.2016.10.019","article-title":"Gout: diagnosis and treatment","volume":"148","author":"Sivera","year":"2017","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.bmc.2024.117874_b0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41584-018-0149-7","article-title":"Prevention and treatment of gout","volume":"15","author":"Stamp","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bmc.2024.117874_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-020-00969-6","article-title":"Beyond medical treatment: surgical treatment of gout","volume":"23","author":"Carcione","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.bmc.2024.117874_b0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11926-019-0843-8","article-title":"Cardiovascular safety of urate lowering therapies","volume":"21","author":"Kang","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.bmc.2024.117874_b0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11926-023-01128-3","article-title":"Pipeline therapies for gout","volume":"26","author":"Yip","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.bmc.2024.117874_b0030","doi-asserted-by":"crossref","first-page":"e15147","DOI":"10.1111\/1756-185X.15147","article-title":"Pathogenesis of gout: exploring more therapeutic target","volume":"27","author":"Xiao","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.bmc.2024.117874_b0035","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004179","article-title":"Optimising gout treatment: insights from a nurse-led cohort study","volume":"10","author":"Rasmussen","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.bmc.2024.117874_b0040","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.rdc.2022.04.003","article-title":"Treatment guidelines in gout","volume":"48","author":"Gelber","year":"2022","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.bmc.2024.117874_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101719","article-title":"Treatment advances in gout","volume":"35","author":"Stamp","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.bmc.2024.117874_b0050","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.2147\/JIR.S434587","article-title":"Mastoparan M suppressed NLRP3 inflammasome activation by inhibiting MAPK\/NF-\u03baB and oxidative stress in gouty arthritis","volume":"16","author":"Yan","year":"2023","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.bmc.2024.117874_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10091880","article-title":"Autoinflammatory features in gouty arthritis","volume":"10","author":"Galozzi","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.bmc.2024.117874_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00211","article-title":"NLRP3 inflammasome-a key player in antiviral responses","volume":"11","author":"Zhao","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2024.117874_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.790072","article-title":"Qingwenzhike prescription alleviates acute lung injury induced by LPS via Inhibiting TLR4\/NF-kB pathway and NLRP3 inflammasome activation","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179954","article-title":"Caffeine inhibits NLRP3 inflammasome activation by downregulating TLR4\/MAPK\/NF-\u03baB signaling pathway in an experimental NASH model","volume":"23","author":"Vargas-Pozada","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2024.117874_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115861","article-title":"NLRP3 inflammasome in hepatic diseases: a pharmacological target","volume":"217","author":"Ramos-Tovar","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0080","article-title":"Gout and diet: a comprehensive review of mechanisms and management","volume":"14","author":"Zhang","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.bmc.2024.117874_b0085","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41584-018-0004-x","article-title":"An update on the genetics of hyperuricaemia and gout","volume":"14","author":"Major","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bmc.2024.117874_b0090","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.3949\/ccjm.75.Suppl_5.S2","article-title":"The pathogenesis of gout","volume":"75","author":"Schumacher","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.bmc.2024.117874_b0095","article-title":"The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics","volume":"11","author":"Wu","year":"2023","journal-title":"PeerJ"},{"key":"10.1016\/j.bmc.2024.117874_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/cells8101215","article-title":"Cellular processing of the ABCG2 transporter-potential effects on gout and drug metabolism","volume":"8","author":"M\u00f3zner","year":"2019","journal-title":"Cells."},{"key":"10.1016\/j.bmc.2024.117874_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154782","article-title":"Mechanisms of theaflavins against gout and strategies for improving the bioavailability","volume":"114","author":"Chen","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bmc.2024.117874_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1220931","article-title":"Causal association between tea intake and risk for gout: a Mendelian randomization study","volume":"14","author":"Liang","year":"2023","journal-title":"Front Genet"},{"key":"10.1016\/j.bmc.2024.117874_b0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063188","article-title":"Uric acid and oxidative stress-relationship with cardiovascular, metabolic, and renal impairment","volume":"23","author":"Gherghina","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2024.117874_b0120","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jhep.2015.11.022","article-title":"Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism","volume":"64","author":"Wan","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2024.117874_b0125","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/0886022X.2022.2036620","article-title":"Research progress on related mechanisms of uric acid activating NLRP3 inflammasome in chronic kidney disease","volume":"44","author":"Wang","year":"2022","journal-title":"Ren Fail"},{"key":"10.1016\/j.bmc.2024.117874_b0130","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bmc.2024.117874_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00262","article-title":"NLRP3 inflammasome and its inhibitors: a review","volume":"6","author":"Shao","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0140","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tibs.2022.10.002","article-title":"The NLRP3 inflammasome: activation and regulation","volume":"48","author":"Xu","year":"2023","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.bmc.2024.117874_b0145","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2024.117874_b0150","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.048041","article-title":"Hyperuricemia causes kidney damage by promoting autophagy and NLRP3-mediated inflammation in rats with urate oxidase deficiency","volume":"14","author":"Wu","year":"2021","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.bmc.2024.117874_b0155","article-title":"Role of NLRP3 in the pathogenesis and treatment of gout arthritis","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2024.117874_b0160","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ade7652","article-title":"Hexokinase dissociation from mitochondria promotes oligomerization of VDAC that facilitates NLRP3 inflammasome assembly and activation","volume":"8","author":"Baik","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.bmc.2024.117874_b0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117874_b0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00710","article-title":"1-Palmitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol (PLAG) mitigates monosodium urate (MSU)-induced acute gouty inflammation in BALB\/c Mice","volume":"11","author":"Shin","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2024.117874_b0175","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ni.1831","article-title":"Thioredoxin-interacting protein links oxidative stress to inflammasome activation","volume":"11","author":"Zhou","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bmc.2024.117874_b0180","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1136\/annrheumdis-2021-220295","article-title":"Mechanosensitive TRPV4 is required for crystal-induced inflammation","volume":"80","author":"Lan","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bmc.2024.117874_b0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13075-019-1974-z","article-title":"Curcumin attenuates MSU crystal-induced inflammation by inhibiting the degradation of I\u03baB\u03b1 and blocking mitochondrial damage","volume":"21","author":"Chen","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bmc.2024.117874_b0190","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4078\/jrd.2022.29.3.140","article-title":"The mechanism of the NLRP3 inflammasome activation and pathogenic implication in the pathogenesis of gout","volume":"29","author":"Kim","year":"2022","journal-title":"J Rheum Dis."},{"key":"10.1016\/j.bmc.2024.117874_b0195","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/1756-185X.14205","article-title":"The current role of NLRP3 inflammasome polymorphism in gout susceptibility","volume":"24","author":"Clavijo-Cornejo","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.bmc.2024.117874_b0200","first-page":"147","article-title":"Inflammasome genes polymorphisms and susceptibility to gout. Is there a link?","volume":"74","author":"Clavijo-Cornejo","year":"2022","journal-title":"Rev Invest Clin"},{"key":"10.1016\/j.bmc.2024.117874_b0205","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","article-title":"Inflammation in gout: mechanisms and therapeutic targets","volume":"13","author":"So","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bmc.2024.117874_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27196213","article-title":"A selective review and virtual screening analysis of natural product inhibitors of the NLRP3 Inflammasome","volume":"27","author":"El-Sayed","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2024.117874_b0215","article-title":"Natural products in attenuating renal inflammation via inhibiting the NLRP3 inflammasome in diabetic kidney disease","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2024.117874_b0220","doi-asserted-by":"crossref","first-page":"5622","DOI":"10.1002\/ptr.8009","article-title":"Targeting the NLRP3 inflammasome for the treatment of hypertensive target organ damage: role of natural products and formulations","volume":"37","author":"Liao","year":"2023","journal-title":"Phytother Res"},{"key":"10.1016\/j.bmc.2024.117874_b0225","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1002\/ptr.7118","article-title":"Medicinal plants and bioactive natural products as inhibitors of NLRP3 inflammasome","volume":"35","author":"Bagherniya","year":"2021","journal-title":"Phytother Res"},{"key":"10.1016\/j.bmc.2024.117874_b0230","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41392-020-0186-y","article-title":"Target identification of natural medicine with chemical proteomics approach: probe synthesis, target fishing and protein identification","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2024.117874_b0235","article-title":"Active substances from callicarpa nudiflora exert anti-cervicitis effects and regulate NLRP3-associated inflammation","volume":"26","author":"Liu","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2024.117874_b0240","doi-asserted-by":"crossref","first-page":"13744","DOI":"10.1038\/s41598-023-40930-y","article-title":"Cardamonin protects against iron overload induced arthritis by attenuating ROS production and NLRP3 inflammasome activation via the SIRT1\/p38MAPK signaling pathway","volume":"13","author":"Li","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2024.117874_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105748","article-title":"Cucurbitacin B inhibits non-small cell lung cancer in vivo and in vitro by triggering TLR4\/NLRP3\/GSDMD-dependent pyroptosis","volume":"170","author":"Yuan","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2024.117874_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104348","article-title":"Coptisine from Coptis chinensis blocks NLRP3 inflammasome activation by inhibiting caspase-1","volume":"147","author":"Wu","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2024.117874_b0255","article-title":"Cichoric acid ameliorates monosodium urate-induced inflammatory response by reducing NLRP3 inflammasome activation via inhibition of NF-kB signaling pathway","volume":"2021","author":"Wang","year":"2021","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.bmc.2024.117874_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102134","article-title":"The Nrf2-NLRP3-caspase-1 axis mediates the neuroprotective effects of Celastrol in Parkinson's disease","volume":"47","author":"Zhang","year":"2021","journal-title":"Redox Biol"},{"key":"10.1016\/j.bmc.2024.117874_b0265","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1249644","article-title":"Pharmacological intervention of curcumin via the NLRP3 inflammasome in ischemic stroke","volume":"14","author":"Du","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0270","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.abb.2019.06.010","article-title":"Chaetocin attenuates gout in mice through inhibiting HIF-1\u03b1 and NLRP3 inflammasome-dependent IL-1\u03b2 secretion in macrophages","volume":"670","author":"Mian","year":"2019","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.bmc.2024.117874_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105906","article-title":"\u03b2-Caryophyllene decreases neuroinflammation and exerts neuroprotection of dopaminergic neurons in a model of hemiparkinsonism through inhibition of the NLRP3 inflammasome","volume":"117","author":"Brand-Rubalcava","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.bmc.2024.117874_b0280","doi-asserted-by":"crossref","first-page":"11782","DOI":"10.1080\/21655979.2022.2072055","article-title":"Cynarin suppresses gouty arthritis induced by monosodium urate crystals","volume":"13","author":"Wu","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.bmc.2024.117874_b0285","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1080\/1028415X.2021.1892985","article-title":"Carvacrol abates NLRP3 inflammasome activation by augmenting Keap1\/Nrf-2\/p62 directed autophagy and mitochondrial quality control in neuropathic pain","volume":"25","author":"Arruri","year":"2022","journal-title":"Nutr Neurosci"},{"key":"10.1016\/j.bmc.2024.117874_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153521","article-title":"Baeckein E suppressed NLRP3 inflammasome activation through inhibiting both the priming and assembly procedure: implications for gout therapy","volume":"84","author":"Lin","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bmc.2024.117874_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01076","article-title":"Budlein A, a sesquiterpene lactone from Viguiera robusta, alleviates pain and inflammation in a model of acute gout arthritis in mice","volume":"9","author":"Fattori","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0300","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ejphar.2014.07.023","article-title":"Doliroside A attenuates monosodium urate crystals-induced inflammation by targeting NLRP3 inflammasome","volume":"740","author":"Wei","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0305","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/art.41245","article-title":"Direct binding to NLRP3 pyrin domain as a novel strategy to prevent NLRP3-driven inflammation and gouty arthritis","volume":"72","author":"Yang","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.bmc.2024.117874_b0310","article-title":"Erianin: a direct NLRP3 inhibitor with remarkable anti-inflammatory activity","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2024.117874_b0315","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/15353702231199076","article-title":"Gentiopicroside alleviates acute myocardial infarction injury in rats by disrupting Nrf2\/NLRP3 signaling","volume":"248","author":"Li","year":"2023","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.bmc.2024.117874_b0320","article-title":"(-)-Epicatechin ameliorates monosodium urate-induced acute gouty arthritis through inhibiting NLRP3 inflammasome and the NF-\u03baB signaling pathway","volume":"13","author":"Wu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0325","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2147\/DDDT.S251623","article-title":"Epigallocatechin-3-gallate protects H2O2-induced nucleus pulposus cell apoptosis and inflammation by inhibiting cGAS\/Sting\/NLRP3 activation","volume":"14","author":"Tian","year":"2020","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.bmc.2024.117874_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.aquatox.2023.106739","article-title":"Eucalyptol alleviates avermectin exposure-induced apoptosis and necroptosis of grass carp hepatocytes by regulating ROS\/NLRP3 axis","volume":"264","author":"Wang","year":"2023","journal-title":"Aquat Toxicol"},{"key":"10.1016\/j.bmc.2024.117874_b0335","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1652244","article-title":"Corilagin restrains NLRP3 inflammasome activation and pyroptosis through the ROS\/TXNIP\/NLRP3 pathway to prevent inflammation","volume":"2022","author":"Luo","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.bmc.2024.117874_b0340","article-title":"The protective effects of neoastilbin on monosodium urate stimulated THP-1-derived macrophages and gouty arthritis in mice through NF-\u03baB and NLRP3 inflammasome pathways","volume":"27","author":"Xu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2024.117874_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155075","article-title":"Levo-tetrahydropalmatine ameliorates neuropathic pain by inhibiting the activation of the Clec7a-MAPK\/NF-\u03baB-NLRP3 inflammasome axis","volume":"121","author":"Wu","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bmc.2024.117874_b0350","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12868","article-title":"Wedelolactone facilitates Ser\/Thr phosphorylation of NLRP3 dependent on PKA signalling to block inflammasome activation and pyroptosis","volume":"53","author":"Pan","year":"2020","journal-title":"Cell Prolif"},{"key":"10.1016\/j.bmc.2024.117874_b0355","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/cbin.11935","article-title":"Ferulic acid relieved ulcerative colitis by inhibiting the TXNIP\/NLRP3 pathway in rats","volume":"47","author":"Yu","year":"2023","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.bmc.2024.117874_b0360","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00721","article-title":"Caffeic acid phenethyl ester prevents colitis-associated cancer by inhibiting NLRP3 inflammasome","volume":"10","author":"Dai","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmc.2024.117874_b0365","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.2147\/JIR.S320912","article-title":"Resveratrol relieves gouty arthritis by promoting mitophagy to inhibit activation of NLRP3 inflammasomes","volume":"14","author":"Fan","year":"2021","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.bmc.2024.117874_b0370","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1142\/S0192415X19500071","article-title":"Rhein, an anthraquinone drug, suppresses the NLRP3 inflammasome and macrophage activation in urate crystal-induced gouty inflammation","volume":"47","author":"Chang","year":"2019","journal-title":"Am J Chin Med"},{"key":"10.1016\/j.bmc.2024.117874_b0375","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01123","article-title":"Trans-chalcone attenuates pain and inflammation in experimental acute gout arthritis in mice","volume":"9","author":"Staurengo-Ferrari","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0380","doi-asserted-by":"crossref","DOI":"10.3390\/cells9091948","article-title":"Loganin attenuates high glucose-induced schwann cells pyroptosis by inhibiting ROS generation and NLRP3 inflammasome activation","volume":"9","author":"Cheng","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bmc.2024.117874_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.114322","article-title":"Leojaponin inhibits NLRP3 inflammasome activation through restoration of autophagy via upregulating RAPTOR phosphorylation","volume":"278","author":"Zhang","year":"2021","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0390","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.intimp.2018.10.025","article-title":"Piperine ameliorated lupus nephritis by targeting AMPK-mediated activation of NLRP3 inflammasome","volume":"65","author":"Peng","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0395","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bcp.2014.10.001","article-title":"Procyanidin B2 inhibits NLRP3 inflammasome activation in human vascular endothelial cells","volume":"92","author":"Yang","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0400","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.580593","article-title":"Gallic acid alleviates gouty arthritis by inhibiting NLRP3 inflammasome activation and pyroptosis through enhancing Nrf2 signaling","volume":"11","author":"Lin","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2024.117874_b0405","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.2147\/DDDT.S356307","article-title":"Palmatine protects against MSU-induced gouty arthritis via regulating the NF-\u03baB\/NLRP3 and Nrf2 pathways","volume":"16","author":"Cheng","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmc.2024.117874_b0410","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/08923973.2019.1590721","article-title":"Pharmacological basis for use of madecassoside in gouty arthritis: anti-inflammatory, anti-hyperuricemic, and NLRP3 inhibition","volume":"41","author":"Lu","year":"2019","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.bmc.2024.117874_b0415","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201905977","article-title":"A new NLRP3 inflammasome inhibitor, dioscin, promotes osteogenesis","volume":"16","author":"Yin","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.bmc.2024.117874_b0420","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02538","article-title":"Pharmacological inhibitors of the NLRP3 inflammasome","volume":"10","author":"Zahid","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2024.117874_b0425","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.drudis.2021.02.018","article-title":"Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases","volume":"26","author":"Vong","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2024.117874_b0430","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41419-019-1413-8","article-title":"Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors","volume":"10","author":"Yang","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bmc.2024.117874_b0435","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.imbio.2019.08.008","article-title":"NLRP3 inflammasome inhibitor glyburide expedites diabetic-induced impaired fracture healing","volume":"224","author":"Yang","year":"2019","journal-title":"Immunobiology"},{"key":"10.1016\/j.bmc.2024.117874_b0440","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jid.2019.05.025","article-title":"Glyburide, a NLRP3 inhibitor, decreases inflammatory response and is a candidate to reduce pathology in leishmania braziliensis infection","volume":"140","author":"Carvalho","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.bmc.2024.117874_b0445","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/tox.22919","article-title":"Glyburide attenuates ozone-induced pulmonary inflammation and injury by blocking the NLRP3 inflammasome","volume":"35","author":"Shao","year":"2020","journal-title":"Environ Toxicol"},{"key":"10.1016\/j.bmc.2024.117874_b0450","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/FJC.0000000000000053","article-title":"A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse","volume":"63","author":"Marchetti","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0455","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1021\/acschemneuro.7b00124","article-title":"Development and characterization of a hydroxyl-sulfonamide analogue, 5-chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis","volume":"8","author":"Guo","year":"2017","journal-title":"ACS Chem Nerosci"},{"key":"10.1016\/j.bmc.2024.117874_b0460","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s12035-017-0467-9","article-title":"NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer's disease","volume":"55","author":"Yin","year":"2018","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.bmc.2024.117874_b0465","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1021\/acs.jmedchem.8b00733","article-title":"Structural insights of benzenesulfonamide analogues as NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization","volume":"61","author":"Fulp","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117874_b0470","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076126","article-title":"The role of post-translational modifications in regulation of NLRP3 inflammasome activation","volume":"24","author":"Xia","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2024.117874_b0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-020-02040-8","article-title":"Isoliquiritin ameliorates depression by suppressing NLRP3-mediated pyroptosis via miRNA-27a\/SYK\/NF-\u03baB axis","volume":"18","author":"Li","year":"2021","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.bmc.2024.117874_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110229","article-title":"Parthenolide targets NLRP3 to treat inflammasome-related diseases","volume":"119","author":"Liu","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0485","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41419-022-04966-8","article-title":"Novel role for caspase 1 inhibitor VX765 in suppressing NLRP3 inflammasome assembly and atherosclerosis via promoting mitophagy and efferocytosis","volume":"13","author":"Jin","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bmc.2024.117874_b0490","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41401-020-0478-3","article-title":"Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma","volume":"42","author":"Li","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bmc.2024.117874_b0495","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2147\/NDT.S364250","article-title":"VRT-043198 ameliorates surgery-induced neurocognitive disorders by restoring the NGF and BNDF expression in aged mice","volume":"18","author":"Tang","year":"2022","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.bmc.2024.117874_b0500","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.18632\/aging.203907","article-title":"Computational research of Belnacasan and new Caspase-1 inhibitor on cerebral ischemia reperfusion injury","volume":"14","author":"Li","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.bmc.2024.117874_b0505","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","article-title":"Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome","volume":"570","author":"Sharif","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117874_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175091","article-title":"Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome","volume":"928","author":"Li","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0515","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1021\/acsmedchemlett.9b00433","article-title":"Discovery of N-cyano-sulfoximineurea derivatives as potent and orally bioavailable NLRP3 inflammasome inhibitors","volume":"11","author":"Agarwal","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117874_b0520","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1471","article-title":"A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis","volume":"13","author":"Klughammer","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.bmc.2024.117874_b0525","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25235533","article-title":"Inhibiting the NLRP3 inflammasome","volume":"25","author":"El-Sharkawy","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2024.117874_b0530","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/cpdd.1162","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral NLRP3 inflammasome inhibitor ZYIL1: first-in-human phase 1 studies (single ascending dose and multiple ascending dose)","volume":"12","author":"Parmar","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.bmc.2024.117874_b0535","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s15010-022-01904-w","article-title":"DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function","volume":"51","author":"Madurka","year":"2023","journal-title":"Infection"},{"key":"10.1016\/j.bmc.2024.117874_b0540","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/cts.13576","article-title":"First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteers","volume":"16","author":"Tang","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.bmc.2024.117874_b0545","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1124\/jpet.123.002013","article-title":"Reversal of high fat diet-induced obesity, systemic inflammation, and astrogliosis by the NLRP3 inflammasome inhibitors NT-0249 and NT-0796","volume":"388","author":"Thornton","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2024.117874_b0550","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1021\/acsmedchemlett.2c00242","article-title":"Discovery and optimization of triazolopyrimidinone derivatives as selective NLRP3 inflammasome inhibitors","volume":"13","author":"Harrison","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117874_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115954","article-title":"MCC950, a NLRP3 inhibitor, ameliorates lipopolysaccharide-induced lung inflammation in mice","volume":"30","author":"Wang","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117874_b0560","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10753-019-01098-8","article-title":"Target of MCC950 in inhibition of NLRP3 inflammasome activation: a literature review","volume":"43","author":"Wu","year":"2020","journal-title":"Inflammation"},{"issue":"6","key":"10.1016\/j.bmc.2024.117874_b0565","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.drudis.2021.02.018","article-title":"Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases","volume":"26","author":"Vong","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2024.117874_b0570","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acs.jmedchem.3c02098","article-title":"Discovery of potent, orally bioavailable, tricyclic NLRP3 inhibitors","volume":"67","author":"Velcicky","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117874_b0575","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02578","article-title":"OLT1177 (Dapansutrile), a selective NLRP3 inflammasome inhibitor, ameliorates experimental autoimmune encephalomyelitis pathogenesis","volume":"10","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2024.117874_b0580","doi-asserted-by":"crossref","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2024.117874_b0585","doi-asserted-by":"crossref","first-page":"24220","DOI":"10.1002\/anie.202109689","article-title":"Accelerated anti-markovnikov alkene hydrosilylation with humic-acid-supported electron-deficient platinum single atoms","volume":"60","author":"Liu","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.bmc.2024.117874_b0590","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1038\/s41467-021-25628-x","article-title":"Efficient access to aliphatic esters by photocatalyzed alkoxycarbonylation of alkenes with alkyloxalyl chlorides","volume":"12","author":"Chen","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.117874_b0595","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP3 to treat inflammasome-driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.bmc.2024.117874_b0600","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148548","article-title":"The role of itaconate in host defense and inflammation","volume":"132","author":"Peace","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmc.2024.117874_b0605","article-title":"4-octyl itaconate as a metabolite derivative inhibits inflammation via alkylation of STING","volume":"42","author":"Li","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmc.2024.117874_b0610","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.tins.2024.01.002","article-title":"Protein-protein interactions regulating \u03b1-synuclein pathology","volume":"47","author":"Wang","year":"2024","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.bmc.2024.117874_b0615","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4155\/fmc-2021-0259","article-title":"Protein-protein interactions by influenza polymerase subunits as drug targets","volume":"14","author":"Felicetti","year":"2022","journal-title":"Fut Med Chem"},{"issue":"7761","key":"10.1016\/j.bmc.2024.117874_b0620","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","article-title":"Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome","volume":"570","author":"Sharif","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117874_b0625","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.117874_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175931","article-title":"Research progress of NLRP3 inflammasome and its inhibitors with aging diseases","volume":"957","author":"Yuan","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2024.117874_b0635","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ddr.21776","article-title":"Oridonin alleviates d-GalN\/LPS-induced acute liver injury by inhibiting NLRP3 inflammasome","volume":"82","author":"Zhang","year":"2021","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.bmc.2024.117874_b0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129621","article-title":"Discovery of novel oridonin sulfamide derivatives as potent NLRP3 inhibitors by a visible-light photocatalysis-enabled peripheral editing","volume":"99","author":"Li","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117874_b0645","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1109938","article-title":"The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors","volume":"13","author":"Zhan","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2024.117874_b0650","doi-asserted-by":"crossref","DOI":"10.3390\/cells13070600","article-title":"The role of the NLRP3 inflammasome in the molecular and biochemical mechanisms of cervical ripening: a comprehensive review","volume":"13","author":"Flis","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bmc.2024.117874_b0655","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12951-023-02246-x","article-title":"The progression of inorganic nanoparticles and natural products for inflammatory bowel disease","volume":"22","author":"Li","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.bmc.2024.117874_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111833","article-title":"Application of omics- and multi-omics-based techniques for natural product target discovery","volume":"141","author":"Zhang","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2024.117874_b0665","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2019.06.004","article-title":"Advancing drug discovery via artificial intelligence","volume":"40","author":"Chan","year":"2019","journal-title":"Trends Pharmacol Sci"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624002888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624002888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T01:17:57Z","timestamp":1725931077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624002888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":133,"alternative-id":["S0968089624002888"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117874","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the treatment of gout with NLRP3 inflammasome inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117874"}}